Highlights on endoglin (CD105): From basic findings towards clinical applications in human cancer

被引：132
作者：
Fonsatti E. [1 ]
Maio M. [1 ,2 ]
机构：
[1] Cancer Bioimmunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico
[2] Div. of Med. Oncology/Immunotherapy, Department of Oncology, University Hospital of Siena
来源：
Journal of Translational Medicine | / 2卷 / 1期
关键词：
CD105; Human Umbilical Vein Endothelial Cell; Hereditary Hemorrhagic Telangiectasia; CD105 Promoter; Vascular Target;
D O I：
10.1186/1479-5876-2-18
中图分类号：
学科分类号：
摘要：
Antibody targeting of tumor-associated vasculature is a promising therapeutic approach in human cancer; however, a specific cell membrane marker for endothelial cells of tumor vasculature has not been discovered yet. Endoglin (CD105) is a cell-surface glycoprotein most recently identified as an optimal indicator of proliferation of human endothelial cells. The finding that CD105 is over-expressed on vascular endothelium in angiogenetic tissues has prompted several pre-clinical studies designed to get a deeper understanding on the role of CD105 in angiogenesis, and to evaluate the most appropriate clinical setting (s) to utilize CD105 as a therapeutic target. In this review, the foreseeable clinical applications of CD105 in human cancer are discussed. © 2004 Fonsatti and Maio; licensee BioMed Central Ltd.
引用
收藏
页数：7
相关论文
共 85 条
[1]  
Smith M.R., Rituximab (monoclonal anti-CD20 antibody): Mechanisms of action and resistance, Oncogene, 22, pp. 7359-7368, (2003)
[2]  
Menard S., Pupa S.M., Campiglio M., Tagliabue E., Biologic and therapeutic role of HER2 in cancer, Oncogene, 22, pp. 6570-6578, (2003)
[3]  
Green M.C., Murray J.L., Hortobagyi G.N., Monoclonal antibody therapy for solid tumors, Cancer Treat. Rev., 26, pp. 269-286, (2000)
[4]  
Brekken R.A., Li C., Kumar S., Strategies for vascular targeting in tumors, Int. J. Cancer, 100, pp. 123-130, (2002)
[5]  
Thorpe P.E., Vascular targeting agents as cancer therapeutics, Clin. Cancer Res., 10, pp. 415-427, (2004)
[6]  
Haruta Y., Seon B.K., Distinct human leukemia-associated cell surface glycoprotein GP160 defined by monoclonal antibody SN6, Proc. Natl. Acad. Sci. U S A, 83, pp. 7898-7902, (1986)
[7]  
Gougos A., Letarte M., Identification of a human endothelial cell antigen with monoclonal antibody 44G4 produced against a pre-B leukemic cell line, J. Immunol., 141, pp. 1925-1933, (1988)
[8]  
Gougos A., Letarte M., Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells, J. Biol. Chem., 265, pp. 8361-8364, (1990)
[9]  
Bellon T., Corbi A., Lastres P., Cales C., Cebrian M., Vera S., Cheifetz S., Massague J., Letarte M., Bernabeu C., Identification and expression of two forms of the human transforming growth factor-beta-binding protein endoglin with distinct cytoplasmic regions, Eur. J. Immunol., 23, pp. 2340-2345, (1993)
[10]  
Lastres P., Martin-Perez J., Langa C., Bernabeu C., Phosphorylation of the human-transforming-growth-factor-β-binding protein endoglin, Biochem. J., 301, pp. 765-768, (1994)
123456789